These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 7330651)

  • 1. [Hyperprolactinemia in metastasizing breast cancer].
    Nagel GA; Wander HE; Blossey HC
    Schweiz Med Wochenschr; 1981 Dec; 111(50):1977-9. PubMed ID: 7330651
    [No Abstract]   [Full Text] [Related]  

  • 2. Importance of serum prolactin determination in metastatic breast cancer patients.
    Mujagić Z; Mujagić H
    Croat Med J; 2004 Apr; 45(2):176-80. PubMed ID: 15103755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Radioimmunochemical analysis in the evaluation of the effectiveness of drug therapy of breast cancer in women of reproductive age].
    Tkacheva GA; Moroz LV; Ivanov VM
    Vestn Akad Med Nauk SSSR; 1984; (5):54-60. PubMed ID: 6741250
    [No Abstract]   [Full Text] [Related]  

  • 4. Prolactin serum level in patients with breast cancer.
    Cohen AD; Cohen Y; Maislos M; Buskila D
    Isr Med Assoc J; 2000 Apr; 2(4):287-9. PubMed ID: 10804904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of surgical psychoncology in breast cancer: perioperative variation of prolactin serum levels in women with operable breast cancer in relation to their maternal psychological behaviour.
    Messina G; Lissoni P; Brivio F; Rovelli F; Fumagalli L; Bartolacelli E; Mazza U; Colombo E; Bertoglio A
    In Vivo; 2008; 22(6):845-8. PubMed ID: 19181018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Which chemotherapy promises the best out-look in metastasizing breast carcinoma?].
    Med Welt; 1983 Jan; 34(4):89-92. PubMed ID: 6827977
    [No Abstract]   [Full Text] [Related]  

  • 7. Node negative breast carcinoma: hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators.
    Patel DD; Bhatavdekar JM; Chikhlikar PR; Ghosh N; Suthar TP; Shah NG; Mehta RH; Balar DB
    J Surg Oncol; 1996 Jun; 62(2):86-92. PubMed ID: 8649046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammary cancer risk: circulating TSH and prolactin, fibrocystic breast disease in chronoepidemiologic perspective.
    Tarquini B; Benvenuti M; Legnaioli M; Bazzani M; Cagnoni M; Halberg F
    Cancer Detect Prev; 1981; 4(1-4):525-34. PubMed ID: 7349819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive review of chemotherapy in patients with metastatic breast cancer.
    Melemed AS; Mockbee C; Orlando M
    J Clin Oncol; 2005 Nov; 23(31):8139-40. PubMed ID: 16258122
    [No Abstract]   [Full Text] [Related]  

  • 10. Prognostic significance of plasma prolactin in breast cancer: comparison with the expression of c erb B-2 oncoprotein.
    Bhatavdekar JM; Patel DD; Sherbet GV; Giri DD; Karelia NH; Vora HH; Shah NG; Suthar TP; Nadkarni SP; Balar DB
    Eur J Surg Oncol; 1993 Oct; 19(5):409-13. PubMed ID: 8104829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolactin and breast cancer.
    Lancet; 1972 Nov; 2(7787):1129-30. PubMed ID: 4117209
    [No Abstract]   [Full Text] [Related]  

  • 12. Prolactin and breast cancer risk.
    Beumont PJ
    Med J Aust; 1991 Feb; 154(3):219. PubMed ID: 1671167
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacogenomics in breast cancer chemotherapy.
    Marsh S; Liu G
    Adv Drug Deliv Rev; 2009 May; 61(5):381-7. PubMed ID: 19100797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes in prolactin plasma levels in relation to menopausal status in primary breast carcinoma].
    Pavić S; Pavić Z
    Med Pregl; 1995; 48(5-6):159-61. PubMed ID: 7565335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy for breast cancer.
    Schnipper LE; Come SE
    Compr Ther; 1980 Oct; 6(10):42-7. PubMed ID: 7449364
    [No Abstract]   [Full Text] [Related]  

  • 16. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
    Beck MT; Chen NY; Franek KJ; Chen WY
    Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between thyroid-pituitary function and response to therapy in patients with recurrent breast cancer.
    Yokoe T; Iino Y; Takei H; Horiguchi J; Koibuchi Y; Maemura M; Ohwada S; Morishita Y
    Anticancer Res; 1996; 16(4A):2069-72. PubMed ID: 8712744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can plasma prolactin predict tamoxifen resistance in patients with advanced breast cancer?
    Bhatavdekar JM; Patel DD; Karelia NH; Shah NG; Ghosh N; Vora HH; Suthar TP; Balar DB; Doctor SS
    Eur J Surg Oncol; 1994 Apr; 20(2):118-21. PubMed ID: 8181575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Proceedings: Role of prolactin in breast cancer. (2)].
    Daigo K; Kato Y; Fujiwara T; Chihara K; Imura H
    Nihon Naibunpi Gakkai Zasshi; 1974 Feb; 50(2):507. PubMed ID: 4476535
    [No Abstract]   [Full Text] [Related]  

  • 20. [Should chemotherapy or endocrine therapy be used as first choice in patients with advanced breast cancer? A status article based on the Cochrane analysis "Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer"].
    Ejlertsen B; Mouridsen H
    Ugeskr Laeger; 2004 Jun; 166(25):2434-6. PubMed ID: 15283108
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.